ADMA Biologics Inc (NASDAQ:ADMA) Receives Consensus Rating of "Buy" from Brokerages

Key Points

• Consensus "Buy": Five analysts covering ADMA Biologics assign a consensus "Buy" rating with an average 12‑month price target of $28, well above the stock's recent trading level (~$10).
• Latest quarter: ADMA reported EPS of $0.20 (meeting estimates) and revenue of $139.16M, up 18.4% year‑over‑year, with a net margin of 28.8% and return on equity of 37.5%.
• Ownership and insider moves: the COO sold 10,096 shares (~$15.63/sh) while a director bought 7,000 shares (~$15.67/sh); insiders hold 3.70% and institutional investors own about 75.68% of the stock.

ADMA Biologics Inc (NASDAQ:ADMA - Get Free Report) has been assigned a consensus recommendation of "Buy" from the five ratings firms that are covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $28.00.

Several research analysts recently issued reports on ADMA shares. Wall Street Zen upgraded ADMA Biologics from a "hold" rating to a "buy" rating in a research report on Saturday, February 28th. Zacks Research raised shares of ADMA Biologics from a "hold" rating to a "strong-buy" rating in a research note on Monday, March 2nd. Mizuho lowered their target price on shares of ADMA Biologics from $30.00 to $24.00 and set an "outperform" rating for the company in a research note on Monday. Cantor Fitzgerald reaffirmed a "neutral" rating on shares of ADMA Biologics in a research note on Thursday, March 26th. Finally, Weiss Ratings reaffirmed a "hold (c)" rating on shares of ADMA Biologics in a research note on Tuesday, December 23rd.

Insider Activity at ADMA Biologics

In other news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the business's stock in a transaction on Monday, March 9th. The shares were sold at an average price of $15.63, for a total transaction of $157,800.48. Following the completion of the sale, the chief operating officer directly owned 466,600 shares of the company's stock, valued at $7,292,958. The trade was a 2.12% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Steve Elms acquired 7,000 shares of the stock in a transaction dated Thursday, March 5th. The shares were bought at an average cost of $15.67 per share, with a total value of $109,690.00. Following the completion of the purchase, the director directly owned 2,038,730 shares in the company, valued at approximately $31,946,899.10. This trade represents a 0.34% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 3.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On ADMA Biologics

Several hedge funds and other institutional investors have recently made changes to their positions in ADMA. Westfield Capital Management Co. LP acquired a new position in shares of ADMA Biologics during the 3rd quarter valued at $74,866,000. Janus Henderson Group PLC lifted its holdings in shares of ADMA Biologics by 3,906.1% during the 4th quarter. Janus Henderson Group PLC now owns 3,936,419 shares of the biotechnology company's stock valued at $71,820,000 after acquiring an additional 3,838,158 shares in the last quarter. Capital Research Global Investors lifted its holdings in shares of ADMA Biologics by 104.0% during the 4th quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company's stock valued at $121,067,000 after acquiring an additional 3,383,559 shares in the last quarter. Caligan Partners LP acquired a new position in shares of ADMA Biologics during the 3rd quarter valued at $38,653,000. Finally, UBS Group AG lifted its holdings in shares of ADMA Biologics by 129.9% during the 4th quarter. UBS Group AG now owns 4,569,343 shares of the biotechnology company's stock valued at $83,345,000 after acquiring an additional 2,581,670 shares in the last quarter. Institutional investors and hedge funds own 75.68% of the company's stock.

ADMA Biologics Stock Performance

NASDAQ:ADMA traded up $0.64 during mid-day trading on Monday, reaching $10.34. The stock had a trading volume of 3,014,744 shares, compared to its average volume of 4,818,364. The company has a debt-to-equity ratio of 0.16, a quick ratio of 3.74 and a current ratio of 6.71. The firm has a market capitalization of $2.46 billion, a price-to-earnings ratio of 17.23 and a beta of 0.82. ADMA Biologics has a twelve month low of $7.21 and a twelve month high of $25.67. The business has a 50 day simple moving average of $14.06 and a 200 day simple moving average of $15.97.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.20. ADMA Biologics had a net margin of 28.80% and a return on equity of 37.52%. The company had revenue of $139.16 million during the quarter, compared to the consensus estimate of $139.80 million. During the same period last year, the firm earned $0.46 EPS. The company's revenue for the quarter was up 18.4% on a year-over-year basis. On average, analysts expect that ADMA Biologics will post 0.51 earnings per share for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company's marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.